KPTI - NASDAQ

Karyopharm Therapeutics Inc.

KPTI·NASDAQ

$9.23

+2.3%

HealthcareBiotechnology

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$209.18M

EPS-17.9300

P/E Ratio-0.41

Earnings Date07/30/2026

108.42M

Assets

-34%

3Y-70.0%

5Y-65.0%

10Y-40.0%

401.34M

Total Liabilities

15%

3Y+7.0%

5Y+53.0%

10Y+2112.0%

-292.93M

Total Equity

57%

3Y+1659.0%

5Y-680.0%

10Y-281.0%

Karyopharm Therapeutics Inc. Funding & Solvency Profile

KPTI · NASDAQ

Current Assets

Cash & Cash Equivalents60.54M

Net Receivables26.18M

Inventory4.04M

Other Current Assets9.19M

Total Current Assets103 M

Non-Current Assets

Property, Plant & Equipment4.65M

Goodwill & Intangible Assets0.00

Long-Term Investments351.00K

Other Non-Current Assets267.00K

Total Non-Current Assets5 M

Total Assets

108.42M

Financial Health Analysis

Current Ratio

1.12x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Working Capital

11 M

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Karyopharm Therapeutics Inc. Balance Sheet

KPTI • NASDAQ

Karyopharm Therapeutics Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	60.5M	62.5M	52.2M	135.2M	190.5M	85.9M	128.9M	118M	69M	49.7M	58.4M	150.6M	156M	391K	6.5M
Short-Term Investments	3.2M	46.2M	139.2M	142.8M	38.2M	163.3M	133.1M	210.2M	77.5M	79.9M	117.3M	55.1M	0.0	0.0	0.0
Cash & Short-Term Investments	63.7M	108.7M	191.4M	278M	228.6M	249.2M	264M	328.2M	146.5M	129.6M	175.6M	205.7M	156M	391K	6.5M
Net Receivables	26.2M	30.8M	27M	47.1M	22.5M	12.9M	7.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	26.2M	30.8M	27M	47.1M	22.5M	12.9M	7.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	4M	4.7M	3M	4.2M	4.1M	2.6M	346K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	14M	9.3M	7.3M	6.4M	1.8M	2.1M	2M	2M	2M	563K	354K
Other Current Assets	9.2M	12.3M	12.5M	20.9M	6.3M	2.5M	-5.8M	6.4M	2M	2.1M	2M	2M	2M	0.0	0.0
Total Current Assets	103.1M	156.5M	233.9M	350.2M	275.6M	276.5M	273.7M	334.6M	148.4M	131.6M	177.6M	207.8M	158M	954K	6.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	4.7M	6.3M	4.9M	7.4M	9.6M	11.6M	3M	3.9M	2.2M	2.8M	3.5M	2.8M	240K	327K	328K
Long-Term Investments	351K	0.0	0.0	0.0	0.0	24.2M	2M	2M	29.4M	45.4M	33.9M	8.7M	0.0	0.0	0.0
Other Non-Current Assets	267K	1.6M	1.6M	633K	20.1M	722K	16.2M	716K	290K	479K	482K	1.2M	30K	30K	30K
Total Non-Current Assets	5.3M	7.9M	6.5M	8M	29.7M	36.5M	21.3M	6.6M	31.9M	48.7M	37.8M	12.6M	270K	357K	358K
Total Assets	108.4M	164.4M	240.4M	358.2M	305.3M	313.1M	295M	341.2M	180.3M	180.4M	215.4M	220.3M	158.2M	1.3M	7.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	4M	5.1M	3.1M	2.8M	1.6M	4.5M	985K	4.3M	5.7M	4.8M	3.8M	6.3M	1.7M	1.1M	1.1M
Accounts Payable	4M	5.1M	3.1M	2.8M	1.6M	4.5M	985K	4.3M	5.7M	4.8M	3.8M	6.3M	1.7M	1.1M	1.1M
Accrued Expenses	0.0	46.7M	44.9M	38.8M	49.4M	52.9M	13.6M	10.1M	4M	3.5M	2.4M	1.6M	100K	302K	278K
Short Term Debt	21M	24.4M	0.0	0.0	0.0	0.0	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	969K	438K	3.3M	2.9M	2.3M	1.9M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	297K	2.3M	9.4M	21.9M	280K	206K	0.0	79K	66K	200K
Other Current Liabilities	66.1M	15.6M	18.2M	21.5M	20.4M	609K	26.1M	23.1M	17.9M	8.2M	8.9M	4.4M	1.4M	486K	497K
Total Current Liabilities	92.1M	92.3M	69.5M	65.9M	73.7M	60.2M	46.4M	46.9M	49.5M	16.5M	15.1M	12.3M	2.9M	1.9M	2.1M
NON-CURRENT LIABILITIES
Long Term Debt	205.9M	162.9M	170.9M	170.1M	169.3M	117.9M	109.9M	102.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	72.3M	0.0	0.0	0.0	0.0	0.0	4.5M	4.5M	0.0	0.0	1.9M	0.0	384K	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	73.6M	-93.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	25.3M	88.5M	133.5M	132.7M	133M	73.1M	0.0	3.9M	1.4M	1.7M	0.0	1.2M	-384K	27.3M	17.8M
Total Non-Current Liabilities	309.3M	258.2M	307.2M	308.9M	311.3M	202.3M	245.2M	111.1M	1.4M	1.7M	1.9M	1.2M	384K	27.3M	17.8M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	-46.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	6.7M	7.2M	6.1M	9M	11.3M	13.2M	14.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	401.3M	350.4M	376.6M	374.8M	385M	262.5M	245.2M	158M	50.8M	18.1M	17.1M	13.5M	3.3M	29.2M	19.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.3M	0.0
Common Stock	14K	13K	12K	12K	8K	7K	7K	6K	5K	4K	4K	3K	3K	0.0	0.0
Additional Paid-In Capital	1.5B	1.4B	1.4B	1.3B	1.1B	1.1B	923.1M	857.2M	625M	528.6M	455.2M	345.2M	217.5M	745K	83K
Retained Earnings	-1.8B	-1.6B	-1.5B	-1.3B	-1.2B	-1.1B	-873.3M	-673.7M	-495.3M	-366.1M	-256.5M	-138.3M	-62.6M	-28.6M	-12.7M
Accumulated Other Comprehensive Income/Loss	71K	-356K	-161K	-638K	191K	518K	-37K	-244K	-217K	-274K	-282K	-29K	-350K	-206K	-84K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.5M	84K
Total Stockholders' Equity	-292.9M	-186M	-136.2M	-16.7M	-79.7M	50.5M	49.8M	183.2M	129.5M	162.2M	198.4M	206.8M	154.9M	-27.9M	-12.7M
Total Equity	-292.9M	-186M	-136.2M	-16.7M	-79.7M	50.5M	49.8M	183.2M	129.5M	162.2M	198.4M	206.8M	154.9M	-27.9M	-12.7M
SUMMARY
Total Liabilities & Equity	108.4M	164.4M	240.4M	358.2M	305.3M	313.1M	295M	341.2M	180.3M	180.4M	215.4M	220.3M	158.2M	1.3M	7.2M
Total Investments	3.6M	46.2M	139.2M	142.8M	38.2M	187.5M	135.1M	212.2M	106.9M	125.3M	151.2M	63.8M	0.0	0.0	0.0
Total Debt	233.6M	194.5M	177M	179.1M	180.6M	131.1M	109.9M	102.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	173.1M	132M	124.8M	43.9M	-9.9M	45.2M	-19M	-15.4M	-69M	-49.7M	-58.4M	-150.6M	-156M	-391K	-6.5M
Shares Outstanding	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280	8,671,280

SEC Filings

KPTI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 28, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
S-3 S-3 N/A	May 04, 2026	May 04, 2026		View Filing
S-3 S-3 N/A	May 04, 2026	May 04, 2026		View Filing
DEF 14A DEF 14A 2026 N/A	April 13, 2026	April 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	February 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 19, 2026	February 18, 2026	2026	View Filing

Showing 1 to 10 of 268 filings

Related Guides

Blog Categories

Continue your KPTI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.